Figure 1. The proportion of CSBM responders over the 2-week treatment period (A), the proportion of SBM responders by ... Figure 1. The proportion of CSBM.

Slides:

Advertisements

Similar presentations

Table 1 Patient characteristics of attendees of the influenza vaccination, irrespective of AF status From: Yield of screening for atrial fibrillation in.

Advertisements

FIGURE 4: Mean change from baseline in iPTH concentration during treatment and 60 days after treatment withdrawal. Data are shown as the mean change ±

Figure 1 Proportion of criteria chosen (as percentages, grouped into issues). From: Developing national obesity policy in middle-income countries: a case.

From: Learning by Working in Big Cities

Fig. 1 Nodes in a conceptual knowledge graph

Figure 1: Pneumomediastinum and subcutaneous emphysema as indicated by the arrows. From: Pneumomediastinum and subcutaneous emphysema after successful.

From: Detection of Bacteriuria by Canine Olfaction

Figure 1. The flow chart illustrates the construction process of anti-CRISPRdb, and the information that users can obtain from anti-CRISPRdb. From: Anti-CRISPRdb:

Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.

ADAb: anti-drug antibody.

FIGURE 1 Kidney biopsies of Patients 1 and 2

Figure 1 Hazard ratios as a function of annual mean PM2

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Figure 1: Axial T2 W images of penis showed a well-defined septated area of 2 cm in the posterior aspect of ... Figure 1: Axial T2 W images.

FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.

FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels

FIGURE 2 Responses to the question: regarding vasoactive drugs, does your centre use the following frequently, rarely ... FIGURE 2 Responses to the question:

FIGURE 1 Maternal (A) urinary aldosterone; (B) plasma active renin; (C) urinary AGT concentrations; and (D) plasma AGT ... FIGURE 1 Maternal (A) urinary.

FIGURE 1 Flow chart of patient enrollment and exclusion

Figure 1. Ratios of observed to expected numbers of exon boundaries aligning to boundaries of domain and disorder ... Figure 1. Ratios of observed to expected.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Fig. 1 Kaplan-Meier plot of cumulative incidence of cancer onset following dermatomyositis diagnosis stratified ... Anti-TIF1-Ab: anti-transcriptional.

Figure 1 Flortaucipir PET MUBADA/PERSI SUVr at baseline, 9 and 18 months for individual subjects. Each subject is ... Figure 1 Flortaucipir PET MUBADA/PERSI.

Fig. 1 Mean change from baseline in ANC ± s. e

Point estimates with ... Point estimates with 95% CI. HR: hip replacement; KR: knee replacement. Unless provided in the caption above, the following copyright.

Figure 1. (A) Ab+ patients showed significantly more often a cognitive impairment compared with ab− patients [57.1% ... Figure 1. (A) Ab+ patients showed.

FIGURE 1 Participant flow diagram. Exercise Counseling Clinic (ECC).

Graph 1. The number of homicide cases per year discussing neuro-evidence. Unless provided in the caption above, the following copyright applies to the.

Figure 1. Analysis of human TRIM5α protein with Blast-Search and PhyML+SMS ‘One click’ workflow. (A) NGPhylogeny.fr ... Figure 1. Analysis of human TRIM5α.

Figure 2. Natural history of chlamydia transmission, with arrows showing the transitions between health states. Figure 2. Natural history of chlamydia.

Figure 1. Mean concentration–time profiles of ascending doses of ivermectin in (a) PSAC and (b) SAC. Weight-dependent ... Figure 1. Mean concentration–time.

Figure 1 Nelson-Aalen estimates of the cumulative incidence rates for patients on versus off IST. ON = optic neuritis; ... Figure 1 Nelson-Aalen estimates.

FIGURE 1 Malta: a plate-style food guide

Figure 1. A, Crude incidence rates per 100 person-years of follow-up and 95% confidence intervals for each solid organ ... Figure 1. A, Crude incidence.

FIGURE 1 Study consort diagram

Fig. 2 Case 2. Levels of serum creatinine and anti-GBM antibodies before and during treatment with cyclophosphamide, ... Fig. 2 Case 2. Levels of serum.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1. Illustration of DGR systems and their prediction using myDGR

FIGURE 1 Food groups consumed (mean, g/d) among US infants and young children by age group and tertile of mean ... FIGURE 1 Food groups consumed (mean,

Figure 1 Study flowchart and patient flow

Figure 1. Schematic diagram of solar energy and coal-fired power generation system. Unless provided in the caption above, the following copyright applies.

Figure 1. Uncertainty reduction, value creation, and appropriation in two case studies. Unless provided in the caption above, the following copyright applies.

Figure 1 Ratio of the geometric mean concentration of hsTnT (A) and sST2 (B) at baseline (BL) and each subsequent ... Figure 1 Ratio of the geometric mean.

Figure 1. Time to clinical stability (a) and time to defervescence (b) in patients with pneumococcal pneumonia. ... Figure 1. Time to clinical stability.

Figure 1. Oncoprint of selected pathogenic alterations detected in ctDNA. Unless provided in the caption above, the following copyright applies to the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Figure 1. MERMAID web server interface (Start page, Parameter page): MERMAID provides two ways to submit a protein ... Figure 1. MERMAID web server interface.

Figure 1. Yvis platform overview

Figure 1. The framework of NetGO with seven steps

Figure 1 Patient disposition

Figure 1 Diagram of patient and procedural follow-up for Cohorts A, B, and C. Cohort A: 6-month OCT and 12-month OCT, ... Figure 1 Diagram of patient and.

Figure 1. Overview of BEECH study exploratory analysis

Figure 1 BM community in the normozoospermic and iNOA human testis parenchyma. Quantification of the 16 S copies/ng in ... Figure 1 BM community in the.

Fig. 1. —Synteny analysis of melon chromosome 1 (brown) and cucumber chromosome 7 (green) based on melon-cucumber ... Fig. 1. —Synteny analysis of melon.

Figure 1. Trial profile. (A) Part A and (B) part B

Figure 1 Design of trials included in individual patient data meta-analysis. Unless provided in the caption above, the following copyright applies to the.

Figure 1 Distribution of WCD use days in WEARIT-II

Figure 1 Correlation between en face Oil-Red O staining and aortic root lesion size vs. plasma cholesterol and ... Figure 1 Correlation between en face.

Figure 1. Excess cost of methicillin-resistant Staphylococcus aureus (MRSA) compared with methicillin-susceptible S. ... Figure 1. Excess cost of methicillin-resistant.

Figure 1 Genetic results. No case had more than one diagnostic result

Figure 1 Grant agencies and charitable foundations supporting Plan S.

Figure 1. (A) Baseline contrast-enhanced CT scan of melanoma patient presenting with metastases in the liver and lymph ... Figure 1. (A) Baseline contrast-enhanced.

Figure 1. Prevalence of parasitic infection and anemia among the children. Unless provided in the caption above, the following copyright applies to the.

Source:Zimnisky (2014). Source:Zimnisky (2014).

Figure 1 Mechanisms of mitral regurgitation.

Fig. 1. —GO categories enriched in gene families showing high or low omega (dN/dS) values for Pneumocystis jirovecii. ... Fig. 1. —GO categories enriched.

Figure 1 ABCDE of primary prevention.2

Figure 1. Hepatitis C screening and diagnostic algorithm at the MSF clinic, Karachi, Pakistan, March 2016–September ... Figure 1. Hepatitis C screening.

Figure 1. The C-Mill and the 7 C-Gait walking-adaptability tasks.

Figure 1. Overall response rates in wild-type versus RAS and RAS/BRAF mutations detected by nanofluidic digital PCR ... Figure 1. Overall response rates.

Presentation transcript:

Figure 1. The proportion of CSBM responders over the 2-week treatment period (A), the proportion of SBM responders by ... Figure 1. The proportion of CSBM responders over the 2-week treatment period (A), the proportion of SBM responders by week (B), and the proportion of CSBM responders by week (C) in COMPOSE-4 (proportion ± 95% CI; FAS). *P < 0.0001 versus placebo. CI, confidence interval; CSBM, complete spontaneous bowel movement; FAS, full analysis set; SBM, spontaneous bowel movement. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com Ann Oncol, Volume 29, Issue 6, 18 April 2018, Pages 1461–1467, https://doi.org/10.1093/annonc/mdy118 The content of this slide may be subject to copyright: please see the slide notes for details.

Figure 2. Proportion of subjects with ≥ 1 SBM (A) or ≥ 1 CSBM (B) at specific time points within 24 h after the initial ... Figure 2. Proportion of subjects with ≥ 1 SBM (A) or ≥ 1 CSBM (B) at specific time points within 24 h after the initial dose of the study drug in COMPOSE-4 (proportion ± 95% CI; FAS). *P < 0.0001 versus placebo. CI, confidence interval; CSBM, complete spontaneous bowel movement; FAS, full analysis set; SBM, spontaneous bowel movement. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com Ann Oncol, Volume 29, Issue 6, 18 April 2018, Pages 1461–1467, https://doi.org/10.1093/annonc/mdy118 The content of this slide may be subject to copyright: please see the slide notes for details.

Figure 3. Kaplan–Meier curve of time to first SBM (A) or CSBM (B) in COMPOSE-4 (FAS). Circles represent censored time. ... Figure 3. Kaplan–Meier curve of time to first SBM (A) or CSBM (B) in COMPOSE-4 (FAS). Circles represent censored time. The time to the first SBM or CSBM was censored for subjects who withdrew from the study before an SBM or CSBM was observed, or if no SBM or CSBM occurred during the 2-week treatment period. CSBM, complete spontaneous bowel movement; FAS, full analysis set; SBM, spontaneous bowel movement. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com Ann Oncol, Volume 29, Issue 6, 18 April 2018, Pages 1461–1467, https://doi.org/10.1093/annonc/mdy118 The content of this slide may be subject to copyright: please see the slide notes for details.

Figure 4. Change from baseline to day 15 of COMPOSE-4 in PAC-SYM (A) and PAC-QOL (B) overall scores and scores for each ... Figure 4. Change from baseline to day 15 of COMPOSE-4 in PAC-SYM (A) and PAC-QOL (B) overall scores and scores for each domain [mean (SD); FAS]. *P = 0.045 versus placebo. <sup>†</sup>P = 0.015 versus placebo. FAS, full analysis set; ns, not significant; PAC-QOL, Patient Assessment of Constipation Quality of Life; PAC-SYM, Patient Assessment of Constipation Symptoms; SD, standard deviation. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com Ann Oncol, Volume 29, Issue 6, 18 April 2018, Pages 1461–1467, https://doi.org/10.1093/annonc/mdy118 The content of this slide may be subject to copyright: please see the slide notes for details.

Figure 5. Change from baseline (predose on day 1 of COMPOSE-4) over time in PAC-SYM (A) and PAC-QOL (B) overall scores ... Figure 5. Change from baseline (predose on day 1 of COMPOSE-4) over time in PAC-SYM (A) and PAC-QOL (B) overall scores and scores for each domain in COMPOSE-5 (mean; FAS). *P ≤ 0.03 versus BL for mean overall scores and scores for each domain of PAC-SYM. <sup>†</sup>P ≤ 0.0001 versus BL for mean overall scores and scores for each domain of PAC-QOL. BL, baseline; FAS, full analysis set; PAC-QOL, Patient Assessment of Constipation Quality of Life; PAC-SYM, Patient Assessment of Constipation Symptoms. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com Ann Oncol, Volume 29, Issue 6, 18 April 2018, Pages 1461–1467, https://doi.org/10.1093/annonc/mdy118 The content of this slide may be subject to copyright: please see the slide notes for details.